Article
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Pharmacotherapy - 1 Jun 2007
Yeh Wei-Shi, Armstrong Edward P, Skrepnek Grant H, Malone Daniel C
Abstract excerpt
STUDY OBJECTIVE: To assess the cost-utility of peginterferon alfa-2a plus ribavirin, peginterferon alfa-2b plus ribavirin, and no therapy for treatment-naïve patients with chronic hepatitis C virus (HCV) infection from the perspective of the Veterans Affairs (VA) health care system by using patient-reported utility scores. DESIGN: Cost-utility analysis using a Markov model. SETTING: Veterans Affairs health care...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.